DiabTec: Mubadala's Strategic Acquisition in Life Sciences

KELIX bio, a wholly owned subsidiary of Mubadala Investment Company, has completed the acquisition of DiabTec LLC, a Julphar subsidiary. This acquisition aligns with Mubadala’s commitment to advancing the UAE's life sciences sector by enhancing biomanufacturing capabilities across the MENA region. The acquisition marks KELIX bio’s fifth strategic acquisition since it was acquired by Mubadala in March 2024. DiabTec's state-of-the-art facility includes 20,000-liter drug substance reactors and a cartridge fill-finish facility built to EU/US FDA standards, making it the only facility of its kind in the GCC. Mubadala's investment addresses global healthcare challenges, including the growing demand for insulin analogues, while also contributing to a more secure and sustainable supply chain. The transaction strengthens Mubadala's role in the pharmaceutical sector and supports its strategy of local manufacturing as part of the UAE's economic diversification. Julphar’s divestment of DiabTec aligns with its strategy to focus on core assets, with support for Mubadala's initiative to bolster the UAE's pharmaceutical sector.